Literature DB >> 20444540

Improvement of neurological symptoms and memory and emotional status in a case of seronegative Sneddon syndrome with cyclophosphamide.

Peter M Hannon1, Sheng-Han Kuo, Adriana M Strutt, Michele K York, Joseph S Kass.   

Abstract

Sneddon syndrome (SS) is characterized by livedo racemosa, recurrent ischemic strokes, and often progressive vascular dementia. Treatment options for SS center on either anticoagulation or immunosuppression to prevent strokes and to dissipate the skin findings, with these modalities based historically on the presence or absence of antiphospholipid antibodies (APA) respectively. However, few effective treatments have been reported to reverse the cognitive decline in SS. We report a case of a woman with seronegative SS (absence of APA) with cognitive decline who demonstrated objective and subjective improvements in her memory and emotional functioning after treatment with cyclophosphamide. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20444540      PMCID: PMC6474237          DOI: 10.1016/j.clineuro.2010.04.002

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  14 in total

1.  CEREBRO-VASCULAR LESIONS AND LIVEDO RETICULARIS.

Authors:  I B SNEDDON
Journal:  Br J Dermatol       Date:  1965-04       Impact factor: 9.302

2.  Sneddon's syndrome--an inflammatory disorder of small arteries followed by smooth muscle proliferation. Immunohistochemical and ultrastructural evidence.

Authors:  N Sepp; B Zelger; G Schuler; N Romani; P Fritsch
Journal:  Am J Surg Pathol       Date:  1995-04       Impact factor: 6.394

3.  Anticardiolipin antibodies in Sneddon's syndrome.

Authors:  L A Kalashnikova; E L Nasonov; A E Kushekbaeva; L A Gracheva
Journal:  Neurology       Date:  1990-03       Impact factor: 9.910

4.  Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients.

Authors:  C Francès; T Papo; B Wechsler; J L Laporte; V Biousse; J C Piette
Journal:  Medicine (Baltimore)       Date:  1999-07       Impact factor: 1.889

5.  Therapy of Sneddon syndrome.

Authors:  Agnes Flöel; Tanya Imai; Hubertus Lohmann; Florian Bethke; Cord Sunderkötter; Dirk W Droste
Journal:  Eur Neurol       Date:  2002       Impact factor: 1.710

6.  Sneddon's syndrome: a cause of cognitive decline in young adults.

Authors:  J C Adair; K B Digre; R M Swanda; M F Hartshorne; R R Lee; T M Constantino; J E Knoefel
Journal:  Neuropsychiatry Neuropsychol Behav Neurol       Date:  2001 Jul-Sep

7.  The natural course of Sneddon syndrome: clinical and magnetic resonance imaging findings in a prospective six year observation study.

Authors:  S M Boesch; A L Plörer; A J Auer; W Poewe; F T Aichner; S R Felber; N T Sepp
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

8.  Sneddon's syndrome is a thrombotic vasculopathy: neuropathologic and neuroradiologic evidence.

Authors:  D H Geschwind; M FitzPatrick; P S Mischel; J L Cummings
Journal:  Neurology       Date:  1995-03       Impact factor: 9.910

Review 9.  Familial inflammatory Sneddon's syndrome-case report and review of the literature.

Authors:  M Szmyrka-Kaczmarek; T Daikeler; D Benz; I Koetter
Journal:  Clin Rheumatol       Date:  2004-08-31       Impact factor: 2.980

10.  Sneddon's syndrome with granulomatous leptomeningeal infiltration.

Authors:  R L Boortz-Marx; H B Clark; S Taylor; K M Wesa; D C Anderson
Journal:  Stroke       Date:  1995-03       Impact factor: 7.914

View more
  1 in total

Review 1.  Sneddon's syndrome: a comprehensive review of the literature.

Authors:  Shengjun Wu; Ziqi Xu; Hui Liang
Journal:  Orphanet J Rare Dis       Date:  2014-12-31       Impact factor: 4.123

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.